Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in United Arab Emirates has witnessed significant growth in recent years, driven by various factors such as increasing awareness about viral infections, rising healthcare expenditure, and the growing prevalence of viral diseases.
Customer preferences: Customers in the United Arab Emirates are increasingly opting for antiviral drugs as a preventive measure against viral infections. This is mainly due to the rising incidence of viral diseases such as influenza, hepatitis, and HIV/AIDS in the region. Additionally, the growing awareness about the benefits of antiviral drugs in treating viral infections has also contributed to the increased demand for these drugs.
Trends in the market: One of the major trends in the Antiviral Drugs market in United Arab Emirates is the increasing use of combination therapies. Combination therapies involve the use of two or more antiviral drugs to treat viral infections. This approach has been found to be more effective in treating viral infections than using a single drug. Another trend in the market is the growing popularity of generic antiviral drugs. Generic drugs are cheaper than branded drugs and are becoming increasingly popular among patients who cannot afford expensive branded drugs.
Local special circumstances: The United Arab Emirates has a high prevalence of viral diseases such as hepatitis and HIV/AIDS. This has led to a high demand for antiviral drugs in the country. Additionally, the government of the United Arab Emirates has taken various initiatives to improve the healthcare infrastructure in the country, which has also contributed to the growth of the Antiviral Drugs market.
Underlying macroeconomic factors: The Antiviral Drugs market in United Arab Emirates is also being driven by various macroeconomic factors such as increasing healthcare expenditure and the growing population. The government of the United Arab Emirates has been investing heavily in the healthcare sector, which has led to the development of world-class healthcare infrastructure in the country. Additionally, the growing population in the country has also contributed to the increased demand for healthcare services, including antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
